NEW ORLEANS — HIV-positive status may be associated with increased risks for complications and poor postoperative total joint arthroplasty outcomes, according to results presented here.
“This study highlights the increased rates of systemic complication in patients who are HIV positive undergoing primary hip, knee and shoulder arthroplasty, and underscores the need for optimizing these patients during perioperative care, particularly looking at stabilizing and optimizing hematologic status, as well as enhancing venous thromboembolic event prophylaxis,” Zbigniew Gugala, MD,

Chiesi Global Rare Diseases announced the FDA approved lomitapide capsules for treatment of homozygous familial hypercholesterolemia in children aged 2 years and older.
As Healio previously reported, lomitapide (Juxtapid) was approved in 2012 for treatment of adult patients with homozygous familial hypercholesterolemia (HoFH), when used alongside with diet and other lipid-lowering therapies. At the time, the medication was produced by Aegerion Pharmaceuticals.
HoFH is considered an ultra-rare genetic disease, impacting as few as 1 in 360,000 people worldwide, according to a company press

The impact of neflamapimod on neurofilament light levels will be examined in a study of approximately 35 patients with ALS, facilitated by the EXPERTS-ALS platform, according to a press release from CervoMed Inc.
This small-molecule drug can cross the blood-brain barrier and selectively inhibit the p38 MAP kinase alpha isoform, the company said; p38 kinase drives neuroinflammation and synaptic dysfunction.
“Primary treatment for familiar forms of ALS, which account for approximately 95% of cases, is mainly supportive,” CervoMed CEO John Alam, MD, told Healio, addressing the patient’s

Children and adolescents with diabetes using inhaled insulin had an increase in HbA1c from baseline to 1 year, according to data from the INHALE-1 extension trial published in Diabetes Technology & Therapeutics.
As Healio previously reported, children and adolescents using technosphere insulin (Afrezza, MannKind Pharma) in the INHALE-1 trial had a similar HbA1c at 26 weeks as those receiving a rapid-acting analog insulin. In 1-year data from the trial, researchers found that youths who received technosphere insulin for 1 year experienced a significant increase in HbA1c that primarily

WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Michael S. Ip, MD, discusses a real-world study in eyes with geographic atrophy due to nonexudative age-related macular degeneration.
Ip, of Doheny Eye Center UCLA Arcadia, said the efficacy and safety findings for Syfovre (pegcetacoplan injection, Apellis) were “reassuring.” Results showed the rate of adverse effects was low.
“At least in one large private practice setting, the real-world results quite mirror what were seen in the phase 3 OAKS and DERBY clinical trials,” he told Healio.